Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03020784 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of PF-06818883 in Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03020784: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT03020784 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03020784, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Safety, Tolerability and Pharmacokinetics of PF-06818883
Primary Outcome
An assessment of Adverse Events
Interventions
- DRUG Placebo
- DRUG PF-06818883
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2017-06-13 |
| Phase | Phase 1 |
Why NCT03020784 stopped before completion
NCT03020784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03020784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03020784 about?
NCT03020784 is a clinical study titled "Safety and Tolerability of PF-06818883 in Healthy Subjects". Safety, Tolerability and Pharmacokinetics of PF-06818883
What is the current status of trial NCT03020784?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-11-11. Estimated completion is 2017-06-13.
What interventions are being tested in trial NCT03020784?
The interventions under investigation include: Placebo (DRUG), PF-06818883 (DRUG).
Who is sponsoring clinical trial NCT03020784?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03020784's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI